DRS vs RARE · P/E 43, rev $1.76B vs rev $350.0M
Leonardo DRS, Inc. Common Stock (DRS) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
Leonardo DRS, Inc. Common Stock (DRS) is a aerospace & defense company listed on US.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported DRS revenue for 2026-06-30 was $1.76B. Net income was $148.0M. DRS currently screens at market cap $12.31B and trailing P/E 43.1.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
DRS currently screens at market cap $12.31B and trailing P/E 43.1. RARE currently screens at market cap $2.79B.
Not investment advice. Open the DRS and RARE stock pages for the full models.
Not investment advice.